Multi-modal imaging and pharmacokinetic modeling shed light on mechanism of action of anti-angiogenic therapy in malignant gliomas

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216305%3A26220%2F10%3APU89748" target="_blank" >RIV/00216305:26220/10:PU89748 - isvavai.cz</a>

Result on the web

—

DOI - Digital Object Identifier

—

Result language

čeština

Original language name

Multi-modal imaging and pharmacokinetic modeling shed light on mechanism of action of anti-angiogenic therapy in malignant gliomas

Original language description

Glioblastoma multiforme (GBM) is the most common primary brain tumour in adults. Despite important progress in the molecular characterization of GBMs in recent years, treatment efficacy has only improved marginally and median survival after diagnosis isstill limited to about 14 months. GBMs are highly vascularised tumors and endothelial cell proliferation is one of the neuropathological hallmarks of the disease. Therefore the concept of interfering with blood vessel formation has long been proposed asa promising strategy against GBM. Recent clinical trials have shown good radiological response rates with bevacizumab, an antibody against vascular endothelial growth factor (VEGF). Yet, it is currently not known through which biological mechanisms bevacizumab exerts its effect, and whether it has a true anti-tumor effect.

Czech name

Multi-modal imaging and pharmacokinetic modeling shed light on mechanism of action of anti-angiogenic therapy in malignant gliomas

Czech description

Glioblastoma multiforme (GBM) is the most common primary brain tumour in adults. Despite important progress in the molecular characterization of GBMs in recent years, treatment efficacy has only improved marginally and median survival after diagnosis isstill limited to about 14 months. GBMs are highly vascularised tumors and endothelial cell proliferation is one of the neuropathological hallmarks of the disease. Therefore the concept of interfering with blood vessel formation has long been proposed asa promising strategy against GBM. Recent clinical trials have shown good radiological response rates with bevacizumab, an antibody against vascular endothelial growth factor (VEGF). Yet, it is currently not known through which biological mechanisms bevacizumab exerts its effect, and whether it has a true anti-tumor effect.

Type

O - Miscellaneous

CEP classification

FS - Medical facilities, apparatus and equipment

OECD FORD branch

—

Project

<a href="/en/project/GA102%2F09%2F1690" target="_blank" >GA102/09/1690: Improvement of diagnostic value in dynamic contrast enhanced imaging using MRI and ultrasonography in medicine</a><br>

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year

2010

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů